<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02339285</url>
  </required_header>
  <id_info>
    <org_study_id>14-1622</org_study_id>
    <secondary_id>5R01MH101547-02</secondary_id>
    <nct_id>NCT02339285</nct_id>
  </id_info>
  <brief_title>Transcranial Alternating Current Stimulation for Major Depressive Disorder</brief_title>
  <acronym>MDD</acronym>
  <official_title>Pilot Clinical Trial for the Evaluation of Feedback Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the effects of non-invasive transcranial alternating current stimulation (tACS)
      on patients with Major Depressive Disorder (MDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central Hypothesis: Non-invasive brain stimulation that suppresses alpha oscillation reduces
      cortical hyperactivity and causes a clinical improvement

      Aim 1: To conduct a pilot clinical trial to establish feasibility and to collect first
      effectiveness data for the use of tACS to renormalize pathological alpha oscillations in the
      dorsolateral prefrontal cortex (dl-pfc) of unmedicated patients with MDD by comparing MADRS
      scores from baseline and one month follow up.

      Aim 2: Compare alpha oscillation power from resting state EEG recordings on the first and
      last day of stimulation. Collect EEG data at the one month follow up visit using this data to
      analyze alpha frequency activity as a pilot study for derivation of EEG biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2015</start_date>
  <completion_date type="Actual">June 19, 2017</completion_date>
  <primary_completion_date type="Actual">June 19, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score</measure>
    <time_frame>Baseline to F2 (4 weeks after completion of the intervention)</time_frame>
    <description>The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms. This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). A comparison of MADRS scores between baseline and F2 is the primary outcome measure (measured as change from baseline). In these results, negative values will indicate a decrease in depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Alpha Oscillation Power From Resting State EEG Recordings on the First and Last Day of Stimulation</measure>
    <time_frame>Baseline to Day 5 of Stimulation</time_frame>
    <description>The investigators will compare alpha oscillation power from resting state EEG recordings on the first day of stimulation (baseline) and last day of stimulation. The investigators will also collect EEG recordings data at a visit four weeks after completion of the intervention (F2). The investigators will use each of the three EEG recordings as data to analyze alpha frequency activity as a pilot study for derivation of EEG biomarkers. As the stimulation paradigm stimulates the frontal brain regions, the investigators will analyze alpha power change in all brain regions as well as frontal regions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alpha Oscillation Power From Resting State EEG Recordings on the First of Stimulation to 4 Weeks After Completion of Intervention</measure>
    <time_frame>Baseline to F2</time_frame>
    <description>The investigators will compare alpha oscillation power from resting state EEG recordings on the first day of stimulation (baseline) and at the follow-up visit four weeks after completion of the intervention. The investigators will also collect EEG on the fifth day of stimulation. The investigators will use each of the three EEG recordings as data to analyze alpha frequency activity as a pilot study for derivation of EEG biomarkers. As the stimulation paradigm stimulates the frontal brain regions, the investigators will analyze alpha power change in all brain regions as well as frontal regions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Hamilton Depression Rating Scale (HDRS) Score</measure>
    <time_frame>Baseline to Day 5 of Stimulation; Baseline to F2</time_frame>
    <description>The HDRS is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 54. A higher score indicates a worse outcome. This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). The investigators will compare the scores between baseline and F2, with negative values indicating a decrease in depressive symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCA) Score</measure>
    <time_frame>Baseline to F2</time_frame>
    <description>This measurement will be taken at baseline (first day of stimulation) and four weeks after completion of the intervention (F2). Total score ranges from 0 to 30, with higher values indicating better cognition. The investigators will compare the scores between baseline and F2. Reported values are the raw change (increase or decrease) from baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Beck Depression Inventory (BDI) Score</measure>
    <time_frame>Baseline to Day 5; Baseline to F2</time_frame>
    <description>This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). Higher scores indicate more depressive symptoms. Total score is out of 63 possible. The investigators will compare the scores between baseline and F2. In these results, negative values indicate a decrease in depressive symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impressions (CGI) Raw Score</measure>
    <time_frame>Day 5; F2 (4 weeks after completion of treatment)</time_frame>
    <description>This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). The investigators will compare the scores between baseline and F2.The reported values are from Item 1 &quot;Severity of Illness&quot; on a likert scale of 1 to 7, with 1=Normal, not at all ill and 7 = Among the most extremely ill patients.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>MDD</condition>
  <arm_group>
    <arm_group_label>tACS (alpha)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (alpha) device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tACS (gamma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (gamma) device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation. Uses tACS (alpha) device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tACS (alpha)</intervention_name>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_label>tACS (alpha)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tACS (gamma)</intervention_name>
    <arm_group_label>tACS (gamma)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18-65 years old

          -  Diagnostic and Statistical Manual of Mental Disorder, 4th edition (DSM-IV) diagnosis
             of MDD; unipolar, non-psychotic

          -  Hamilton Depression Rating Scale score &gt;8

          -  Capacity to understand all relevant risks and potential benefits of the study
             (informed consent)

          -  Meet criteria for low suicide risk

          -  Willing to comply with all study procedures and be available to do so for the duration
             of the study

          -  Women of reproductive potential must use highly effective contraception

        Exclusion Criteria:

          -  DSM-IV diagnosis of alcohol of substance abuse (other than nicotine) within the last
             month or a DSM-IV diagnosis of alcohol or substance dependence (other than nicotine)
             within the last 6 months

          -  Current use of benzodiazepines or anti-epileptic drugs

          -  Current axis I mood, or psychotic disorder other than major depressive disorder

          -  Lifetime comorbid psychiatric bipolar or psychotic disorder

          -  Eating disorder (current or within the past 6 months)

          -  Obsessive-compulsive disorder (lifetime)

          -  Post traumatic stress disorder (PTSD; current or within the last 6 months)

          -  Attention Deficit Hyperactivity Disorder (ADHD; currently under treatment)

          -  Anything that, in the opinion of the investigator, would place the participant at
             increased risk or preclude the participant's full compliance with or completion of the
             study

          -  Neurological disorders, including but not limited to history of seizures (except
             childhood febrile seizures and ECT induced seizures), dementia, history of stroke,
             Parkinson's disease, multiple sclerosis, cerebral aneurism

          -  Medical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or
             renal impairment) or treatment for a medical disorder that could interfere with study
             participation

          -  History of traumatic brain injury, reoccurring seizures or later cognitive
             rehabilitation, or causing cognitive sequelae

          -  Prior brain surgery

          -  Any brain devices/implants, including cochlear implants and aneurysm clips

          -  Co-morbid neurological condition (i.e. seizure disorder, brain tumor)

          -  Non English speakers

          -  Pregnancy, nursing, or if female and fertile, unwilling to use appropriate birth
             control measures during study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Frohlich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina at Chapel Hill, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Chapel Hill Medical School Wing C</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Valiengo L, Bense√±or IM, Goulart AC, de Oliveira JF, Zanao TA, Boggio PS, Lotufo PA, Fregni F, Brunoni AR. The sertraline versus electrical current therapy for treating depression clinical study (select-TDCS): results of the crossover and follow-up phases. Depress Anxiety. 2013 Jul;30(7):646-53. doi: 10.1002/da.22079. Epub 2013 Apr 26.</citation>
    <PMID>23625554</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2015</study_first_posted>
  <results_first_submitted>June 12, 2018</results_first_submitted>
  <results_first_submitted_qc>July 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2018</results_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tACS</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>MDD</keyword>
  <keyword>mood symptoms</keyword>
  <keyword>sham</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02339285/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through advertisements (e.g., online, flyers) and self-identified with depression. Interested participants contacted the study team.</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned to 1 of 3 arms: tACS (alpha), tACS (gamma), or sham stimulation. All conditions were delivered during awake, resting state for 40 minutes on 5 consecutive days. 98 participants signed consent, 40 did not meet criteria, 6 declined participation, and 20 were excluded for other reasons. 32 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>tACS (Alpha)</title>
          <description>10 Hz transcranial alternating current stimulation (tACS) with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
        </group>
        <group group_id="P2">
          <title>tACS (Gamma)</title>
          <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
        </group>
        <group group_id="P3">
          <title>Sham Stimulation</title>
          <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Intervention</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2 Week Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>4 Week Follow-up Visit</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>tACS (Alpha)</title>
          <description>10 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
        </group>
        <group group_id="B2">
          <title>tACS (Gamma)</title>
          <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
        </group>
        <group group_id="B3">
          <title>Sham Stimulation</title>
          <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.30" spread="15.22"/>
                    <measurement group_id="B2" value="35.36" spread="11.56"/>
                    <measurement group_id="B3" value="38.36" spread="13.54"/>
                    <measurement group_id="B4" value="36.69" spread="13.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery-Asberg Depression Rating Scale (MADRS)</title>
          <description>The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.80" spread="6.36"/>
                    <measurement group_id="B2" value="25.00" spread="7.21"/>
                    <measurement group_id="B3" value="24.55" spread="5.18"/>
                    <measurement group_id="B4" value="26.03" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Depression Rating Scale (HDRS)</title>
          <description>The HDRS is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 54. Higher scores indicate more depressive symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.90" spread="4.51"/>
                    <measurement group_id="B2" value="14.64" spread="3.53"/>
                    <measurement group_id="B3" value="14.55" spread="6.12"/>
                    <measurement group_id="B4" value="15.63" spread="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beck Depression Inventory (BDI)</title>
          <description>The BDI is a self-administered questionnaire that measures the occurrence and severity of current depressive symptoms. Total scores range from 0-63 with higher scores indicating higher feelings of being depressed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.60" spread="5.58"/>
                    <measurement group_id="B2" value="28.27" spread="8.81"/>
                    <measurement group_id="B3" value="26.18" spread="9.74"/>
                    <measurement group_id="B4" value="27.03" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montreal Cognitive Assessment (MoCA)</title>
          <description>A basic assessment of cognition. Total score is ranges from 0 to 30 points, with higher values indicating better cognition.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.20" spread="1.99"/>
                    <measurement group_id="B2" value="27.27" spread="1.62"/>
                    <measurement group_id="B3" value="27.82" spread="2.48"/>
                    <measurement group_id="B4" value="27.75" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression (CGI)</title>
          <description>Values reported on Item 1 &quot;Severity of Illness&quot; on the Clinical Global Impressions scale. Patients are scored on a likert scale, with 1 = &quot;Normal, not at all ill&quot; to 7 = &quot;Among the most extremely ill patients.&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.10" spread="0.99"/>
                    <measurement group_id="B2" value="3.82" spread="0.60"/>
                    <measurement group_id="B3" value="3.73" spread="0.79"/>
                    <measurement group_id="B4" value="3.88" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score</title>
        <description>The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms. This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). A comparison of MADRS scores between baseline and F2 is the primary outcome measure (measured as change from baseline). In these results, negative values will indicate a decrease in depressive symptoms.</description>
        <time_frame>Baseline to F2 (4 weeks after completion of the intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>tACS (Alpha)</title>
            <description>10 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>tACS (Gamma)</title>
            <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O3">
            <title>Sham Stimulation</title>
            <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score</title>
          <description>The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms. This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). A comparison of MADRS scores between baseline and F2 is the primary outcome measure (measured as change from baseline). In these results, negative values will indicate a decrease in depressive symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.60" spread="7.75"/>
                    <measurement group_id="O2" value="-8.82" spread="8.94"/>
                    <measurement group_id="O3" value="-8.27" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference baseline and the 4 week follow up in MADRS score between treatment groups.
Alternative hypothesis: There is a difference between baseline and the 4 week follow up MADRS score between treatment groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>F-test; Treatment effect</non_inferiority_desc>
            <p_value>&gt;0.10</p_value>
            <method>ANOVA</method>
            <method_desc>F(2, 29)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference baseline and the 4 week follow up in MADRS score between treatment groups.
Alternative hypothesis: There is a difference between baseline and the 4 week follow up MADRS score between treatment groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>F-test; Session effect</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>F(1, 31)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>F-test; Interaction effect (session x treatment)</non_inferiority_desc>
            <p_value>&gt;0.10</p_value>
            <method>ANOVA</method>
            <method_desc>F(2,29)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alpha Oscillation Power From Resting State EEG Recordings on the First and Last Day of Stimulation</title>
        <description>The investigators will compare alpha oscillation power from resting state EEG recordings on the first day of stimulation (baseline) and last day of stimulation. The investigators will also collect EEG recordings data at a visit four weeks after completion of the intervention (F2). The investigators will use each of the three EEG recordings as data to analyze alpha frequency activity as a pilot study for derivation of EEG biomarkers. As the stimulation paradigm stimulates the frontal brain regions, the investigators will analyze alpha power change in all brain regions as well as frontal regions.</description>
        <time_frame>Baseline to Day 5 of Stimulation</time_frame>
        <population>Only participants that completed all sessions are used in this task (per protocol participants); N = 26</population>
        <group_list>
          <group group_id="O1">
            <title>tACS (Alpha)</title>
            <description>10 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>tACS (Gamma)</title>
            <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O3">
            <title>Sham Stimulation</title>
            <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alpha Oscillation Power From Resting State EEG Recordings on the First and Last Day of Stimulation</title>
          <description>The investigators will compare alpha oscillation power from resting state EEG recordings on the first day of stimulation (baseline) and last day of stimulation. The investigators will also collect EEG recordings data at a visit four weeks after completion of the intervention (F2). The investigators will use each of the three EEG recordings as data to analyze alpha frequency activity as a pilot study for derivation of EEG biomarkers. As the stimulation paradigm stimulates the frontal brain regions, the investigators will analyze alpha power change in all brain regions as well as frontal regions.</description>
          <population>Only participants that completed all sessions are used in this task (per protocol participants); N = 26</population>
          <units>decibel (dB)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Brain Regions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="1.75"/>
                    <measurement group_id="O2" value="0.53" spread="1.79"/>
                    <measurement group_id="O3" value="0.24" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Brain Regions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="1.29"/>
                    <measurement group_id="O2" value="0.12" spread="1.68"/>
                    <measurement group_id="O3" value="-0.02" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference in changes of alpha frequency power between baseline EEG and EEG on Day 5 of Stimulation between treatment groups.
Alternative hypothesis: There is a difference in changes of alpha frequency power between baseline EEG and EEG on Day 5 of Stimulation between treatment groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>F-test; Condition effect</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>F(2,21.595)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference in changes of alpha frequency power between baseline EEG and EEG on Day 5 of Stimulation between treatment groups.
Alternative hypothesis: There is a difference in changes of alpha frequency power between baseline EEG and EEG on Day 5 of Stimulation between treatment groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>F-test; Region effect (region defined as region of brain - frontal, parietal, occipital temporal)</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>F(3, 79.358)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference in changes of alpha frequency power between baseline EEG and EEG on Day 5 of Stimulation between treatment groups.
Alternative hypothesis: There is a difference in changes of alpha frequency power between baseline EEG and EEG on Day 5 of Stimulation between treatment groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>F-test; Interaction effect (region x condition)</non_inferiority_desc>
            <p_value>&gt;0.10</p_value>
            <method>ANOVA</method>
            <method_desc>F(6, 68.284)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alpha Oscillation Power From Resting State EEG Recordings on the First of Stimulation to 4 Weeks After Completion of Intervention</title>
        <description>The investigators will compare alpha oscillation power from resting state EEG recordings on the first day of stimulation (baseline) and at the follow-up visit four weeks after completion of the intervention. The investigators will also collect EEG on the fifth day of stimulation. The investigators will use each of the three EEG recordings as data to analyze alpha frequency activity as a pilot study for derivation of EEG biomarkers. As the stimulation paradigm stimulates the frontal brain regions, the investigators will analyze alpha power change in all brain regions as well as frontal regions.</description>
        <time_frame>Baseline to F2</time_frame>
        <population>Only participants that completed all sessions are used in this task (per protocol participants); N = 26</population>
        <group_list>
          <group group_id="O1">
            <title>tACS (Alpha)</title>
            <description>10 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>tACS (Gamma)</title>
            <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O3">
            <title>Sham Stimulation</title>
            <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alpha Oscillation Power From Resting State EEG Recordings on the First of Stimulation to 4 Weeks After Completion of Intervention</title>
          <description>The investigators will compare alpha oscillation power from resting state EEG recordings on the first day of stimulation (baseline) and at the follow-up visit four weeks after completion of the intervention. The investigators will also collect EEG on the fifth day of stimulation. The investigators will use each of the three EEG recordings as data to analyze alpha frequency activity as a pilot study for derivation of EEG biomarkers. As the stimulation paradigm stimulates the frontal brain regions, the investigators will analyze alpha power change in all brain regions as well as frontal regions.</description>
          <population>Only participants that completed all sessions are used in this task (per protocol participants); N = 26</population>
          <units>decibel (dB)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Brain Regions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="2.35"/>
                    <measurement group_id="O2" value="0.09" spread="1.76"/>
                    <measurement group_id="O3" value="0.55" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal Brain Regions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="1.89"/>
                    <measurement group_id="O2" value="0.00" spread="1.60"/>
                    <measurement group_id="O3" value="0.41" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference in changes of alpha frequency power between baseline EEG and EEG 4 weeks after completion of the intervention between treatment groups.
Alternative hypothesis: There is a difference in changes of alpha frequency power between baseline EEG and EEG 4 weeks after completion of the intervention between treatment groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.10</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Hamilton Depression Rating Scale (HDRS) Score</title>
        <description>The HDRS is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 54. A higher score indicates a worse outcome. This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). The investigators will compare the scores between baseline and F2, with negative values indicating a decrease in depressive symptoms.</description>
        <time_frame>Baseline to Day 5 of Stimulation; Baseline to F2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>tACS (Alpha)</title>
            <description>10 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>tACS (Gamma)</title>
            <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O3">
            <title>Sham Stimulation</title>
            <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Depression Rating Scale (HDRS) Score</title>
          <description>The HDRS is a clinician-administered depression assessment and consists of 17 items with a total score range from 0 to 54. A higher score indicates a worse outcome. This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). The investigators will compare the scores between baseline and F2, with negative values indicating a decrease in depressive symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5 change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.00" spread="3.09"/>
                    <measurement group_id="O2" value="-4.45" spread="5.41"/>
                    <measurement group_id="O3" value="-3.09" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F2 change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.50" spread="5.04"/>
                    <measurement group_id="O2" value="-4.73" spread="5.61"/>
                    <measurement group_id="O3" value="-4.64" spread="6.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Montreal Cognitive Assessment (MoCA) Score</title>
        <description>This measurement will be taken at baseline (first day of stimulation) and four weeks after completion of the intervention (F2). Total score ranges from 0 to 30, with higher values indicating better cognition. The investigators will compare the scores between baseline and F2. Reported values are the raw change (increase or decrease) from baseline.</description>
        <time_frame>Baseline to F2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>tACS (Alpha)</title>
            <description>10 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>tACS (Gamma)</title>
            <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O3">
            <title>Sham Stimulation</title>
            <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Montreal Cognitive Assessment (MoCA) Score</title>
          <description>This measurement will be taken at baseline (first day of stimulation) and four weeks after completion of the intervention (F2). Total score ranges from 0 to 30, with higher values indicating better cognition. The investigators will compare the scores between baseline and F2. Reported values are the raw change (increase or decrease) from baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.53"/>
                    <measurement group_id="O2" value="1.27" spread="1.35"/>
                    <measurement group_id="O3" value="1.09" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Beck Depression Inventory (BDI) Score</title>
        <description>This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). Higher scores indicate more depressive symptoms. Total score is out of 63 possible. The investigators will compare the scores between baseline and F2. In these results, negative values indicate a decrease in depressive symptoms.</description>
        <time_frame>Baseline to Day 5; Baseline to F2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>tACS (Alpha)</title>
            <description>10 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>tACS (Gamma)</title>
            <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O3">
            <title>Sham Stimulation</title>
            <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Beck Depression Inventory (BDI) Score</title>
          <description>This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). Higher scores indicate more depressive symptoms. Total score is out of 63 possible. The investigators will compare the scores between baseline and F2. In these results, negative values indicate a decrease in depressive symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5 Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.60" spread="6.42"/>
                    <measurement group_id="O2" value="-9.64" spread="10.07"/>
                    <measurement group_id="O3" value="-7.18" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F2 change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.80" spread="12.39"/>
                    <measurement group_id="O2" value="-11.09" spread="11.68"/>
                    <measurement group_id="O3" value="-10.64" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinical Global Impressions (CGI) Raw Score</title>
        <description>This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). The investigators will compare the scores between baseline and F2.The reported values are from Item 1 &quot;Severity of Illness&quot; on a likert scale of 1 to 7, with 1=Normal, not at all ill and 7 = Among the most extremely ill patients.</description>
        <time_frame>Day 5; F2 (4 weeks after completion of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>tACS (Alpha)</title>
            <description>10 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O2">
            <title>tACS (Gamma)</title>
            <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
          </group>
          <group group_id="O3">
            <title>Sham Stimulation</title>
            <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions (CGI) Raw Score</title>
          <description>This measurement will be taken at baseline (Day 1 of Stimulation), Day 5 of Stimulation, 2 weeks after completion of the intervention (F1), and 4 weeks after completion of the intervention (F2). The investigators will compare the scores between baseline and F2.The reported values are from Item 1 &quot;Severity of Illness&quot; on a likert scale of 1 to 7, with 1=Normal, not at all ill and 7 = Among the most extremely ill patients.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread="0.95"/>
                    <measurement group_id="O2" value="3.73" spread="0.65"/>
                    <measurement group_id="O3" value="3.73" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F2 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="1.37"/>
                    <measurement group_id="O2" value="3.82" spread="0.75"/>
                    <measurement group_id="O3" value="3.45" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the intervention period and throughout F2 (4 weeks after completion of the intervention), for an average of 5 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>tACS (Alpha)</title>
          <description>10 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
        </group>
        <group group_id="E2">
          <title>tACS (Gamma)</title>
          <description>40 Hz transcranial alternating current stimulation with a peak-to-peak amplitude of 2 mA for 40 minutes</description>
        </group>
        <group group_id="E3">
          <title>Sham Stimulation</title>
          <description>Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Flavio Frohlich</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>(919) 966-4584</phone>
      <email>flavio_frohlich@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

